Please login to the form below

Not currently logged in
Email:
Password:

treatment access

This page shows the latest treatment access news and features for those working in and with pharma, biotech and healthcare.

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Novartis and NHS England reach ‘landmark’ deal for Zolgensma gene therapy for SMA

Novartis Gene Therapies and NHS England have reached a ‘landmark’ deal for Zolgensma gene therapy that gives patients with spinal muscular atrophy (SMA) access to the innovative treatment. . ... The managed access agreement for Spinraza that was

Latest news

More from news
Approximately 1 fully matching, plus 221 partially matching documents found.

Latest Intelligence

  • Could the rare disease community teach pharma a lesson? Could the rare disease community teach pharma a lesson?

    by Leigh Ansell. Patient support programmes (PSPs) provide help, information and advice to patients, from diagnosis through treatment. ... They get involved with patient organisations, from fundraising and events to advocacy for research funding and

  • Rare genetic diseases – what’s in store for 2021? Rare genetic diseases – what’s in store for 2021?

    The cross-collaboration has also brought forward fundamental changes and breakthroughs for the treatment of many rare genetic diseases. ... We’re looking at digital advances that would improve access to treatment and the overall patient experience.

  • New truths and realities in these strange times New truths and realities in these strange times

    The issue may be as simple as not being able to access their physician/GP in the usual manner, not having the usual access to their medications as regularly (if at ... Patients are also worried about access to care or treatment; the difficulties of

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimer’s disease

    It will take multiple evolutions before we get an AD treatment equivalent to today’s smartphones. ... Yet a product only succeeds if patients can access it, and smooth market entry in AD.

  • A market-adapted agile approach to launch excellence A market-adapted agile approach to launch excellence

    relevance. 2. Less white space product differentiation. In crowded disease areas where compounds may show only incremental benefit, payers often make cross-product comparisons, differentiating and restricting treatment access. ... tactics for bolder

More from intelligence
Approximately 1 fully matching, plus 53 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Living with psoriasis: a patient perspective Living with psoriasis: a patient perspective

    For those living with it, navigating a complex treatment pathway, with limited access to specialist dermatologists[ii] and whilst managing flare-ups, are significant challenges to achieving long-term goals. ... Activating people living with psoriasis to

  • What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health

    Access to care and treatment. Access to research. Financial burden. Despite scientific development, greater healthcare awareness and technological advancements, time to diagnosis remains a significant challenge for people living with rare

  • If our patients are diverse, why are clinical trials so white?

    As a result, it’s very likely that only wealthier people from urban areas will begin their treatment journey at these larger research institutions with the proper resources for and access ... Ninlaro is an oral treatment for multiple myeloma indicated

  • Are biobetters a market access opportunity?

    Ensuring market access for biobetters. Biobetters provide stepped up value to patients, such as increased convenience and further treatment options should disease progression occur. ... To achieve this, biobetters must address an unmet patient need or

  • EPG Health EPG Health

    Providing a trusted learning environment, with convenient access to content that supports HCP treatment decisions and patient outcomes,   Medthority is funded through pharmaceutical educational grants and sponsorship. ... Optimise content for

More from PMHub
Approximately 0 fully matching, plus 30 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics